Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMMFWOJ)

Drug Name
Probenecid Drug Info
Synonyms
Apurina; Bencid; Benecid; Benemid; Benemide; Benuryl; Panuric; Parabenem; Probalan; Probampacin; Probecid; Proben; Probenecida; Probenecide; Probenecidum; Probenemid; Probenicid; Probenid; Probexin; Prolongine; Robenecid; Sulprin; Tubophan; Uricosid; Urocid; Biokanol Brand of Probenecid; ICN Brand of Probenecid; IDIS Brand of Probenecid; Major Brand of Probenecid; Martec Brand of Probenecid; Merck Brand of Probenecid; Ophthalmic Brand of Probenecid; Parmed Brand of Probenecid; Probenecid Major Brand; Probenecid Martec Brand; Probenecid Parmed Brand; Probenecid Weimer; Probenecid Zenith Brand; Probenecid acid; Synergid R; Valdecasas Brand of Probenecid; Zenith Brand of Probenecid; Benemid (TN); Benuryl (TN); Col-BENEMID; ColBenemid (co mponent of); ColBenemid (component of); P-[Dipropylsulfamoyl]benzoic acid; Polycillin-BRB; Pro-Cid; Probenecida [INN-Spanish]; Probenecide [INN-French]; Probenecidum [INN-Latin]; P-(Dipropylsulfamoyl)benzoic acid; P-(Dipropylsulfamyl)benzoic acid; Polycillin-PRB (component of); Probenecid [INN:BAN:JAN]; Probenecid (JP15/USP/INN); 4-((Dipropylamino)sulfonyl)benzoic acid;4-(Di-n-propylsulfamoyl)benzoesaeure; 4-(Dipropylsulfamoyl)benzoic acid; 4-(N,N-Dipropylsulfamoyl)benzoesaeure; 4-[(dipropylamino)sulfonyl]benzoic acid
Therapeutic ClassUricosuric Agents
Cross-matching ID
PubChem CID
4911
ChEBI ID
CHEMBL897
CAS Number
CAS 57-66-9
TTD Drug ID
D0L7FM
VARIDT Drug ID
DR00232
INTEDE Drug ID
DR1341
ACDINA Drug ID
D00557

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Primary bile acid biosynthesis 1.81 1.19e-1 15/17 (88.24%) AMACR;CH25H;BAAT;...
Antigen processing and presentation 1.73 1.85e-1 60/78 (76.92%) PDIA3;CTSS;CD8A;...
Metabolism of xenobiotics by cytochrome P450 1.72 1.43e-1 49/77 (63.64%) AKR7A2;AKR7A3;GSTO1;...
Renin secretion 1.71 1.13e-1 61/69 (88.41%) CALML5;AGTR1;GNAI1;...
Glycolysis / Gluconeogenesis 1.71 9.06e-2 56/67 (83.58%) PGAM1;PKM;ALDH3A1;...
Progesterone-mediated oocyte maturation 1.67 1.03e-1 75/100 (75%) CCNB2;KRAS;GNAI1;...
Purine metabolism 1.65 1.12e-1 102/129 (79.07%) AK4;HPRT1;NME4;...
Gastric acid secretion 1.59 1.58e-1 63/76 (82.89%) KCNJ15;CALML5;GNAI1;...
Vasopressin-regulated water reabsorption 1.52 2.82e-1 40/44 (90.91%) CREB3L1;DYNLL1;AQP4;...
Melanogenesis 1.52 2.56e-1 74/101 (73.27%) CALML5;KRAS;GNAI1;...
Mucin type O-glycan biosynthesis 1.51 2.51e-1 20/36 (55.56%) GALNT3;ST6GALNAC2;GALNT1;...
Lysine degradation 1.51 2.36e-1 51/63 (80.95%) SMYD2;SUV39H1;DHTKD1;...
Human immunodeficiency virus 1 infection 1.49 2.44e-1 189/212 (89.15%) CCNB2;PDIA3;CALML5;...
Fc gamma R-mediated phagocytosis 1.49 2.44e-1 79/97 (81.44%) LYN;PAK1;ARPC5L;...
Cell cycle 1.46 2.86e-1 110/124 (88.71%) E2F2;CCNB2;PCNA;...
RNA transport 1.45 2.79e-1 128/186 (68.82%) SUMO3;EIF4A3;NXT1;...
Natural killer cell mediated cytotoxicity 1.44 2.80e-1 99/131 (75.57%) TNFSF10;KRAS;PAK1;...
Ubiquinone and other terpenoid-quinone biosynthesis 1.44 2.73e-1 9/11 (81.82%) HPD;NQO1;COQ2;...
Pyrimidine metabolism 1.43 2.68e-1 40/56 (71.43%) NME4;TYMS;DCK;...
Other types of O-glycan biosynthesis 1.40 3.31e-1 29/47 (61.7%) GALNT3;GALNT1;POGLUT1;...
Vibrio cholerae infection 1.37 4.03e-1 44/50 (88%) ATP6V1G1;ATP6V1D;TJP2;...
Mismatch repair 1.36 3.94e-1 22/23 (95.65%) PCNA;MSH6;MSH2;...
Human cytomegalovirus infection 1.35 4.05e-1 201/225 (89.33%) E2F2;CCL5;PDIA3;...
Inflammatory mediator regulation of TRP channels 1.34 4.01e-1 82/98 (83.67%) CALML5;PTGER2;BDKRB1;...
Bile secretion 1.32 3.99e-1 68/90 (75.56%) SLC4A4;AQP9;ATP1B3;...
Ribosome 1.29 3.96e-1 113/158 (71.52%) MRPS2;MRPS16;MRPL17;...
Thiamine metabolism 1.28 4.01e-1 12/15 (80%) AK4;ALPL
Collecting duct acid secretion 1.27 4.05e-1 22/27 (81.48%) ATP6V1G1;ATP6V1D;ATP6V1C1;...
Central carbon metabolism in cancer 1.27 4.05e-1 67/70 (95.71%) PGAM1;KRAS;SCO2;...
Herpes simplex virus 1 infection 1.26 3.99e-1 165/498 (33.13%) CCL5;PDIA3;DAXX;...
Fluid shear stress and atherosclerosis -1.16 5.64e-1 123/139 (88.49%) IL1B;CTNNB1;ARHGEF2;...
Prostate cancer -1.16 5.66e-1 93/97 (95.88%) CREB1;PIK3CA;AR;...
Mitophagy -1.16 5.64e-1 56/68 (82.35%) PINK1;HIF1A;UBC;...
Cysteine and methionine metabolism -1.17 5.66e-1 43/50 (86%) AHCY;BCAT2;MAT1A;...
Arachidonic acid metabolism -1.18 5.64e-1 48/61 (78.69%) ALOX5;PTGDS;PLA2G4C;...
AMPK signaling pathway -1.27 5.40e-1 106/120 (88.33%) TSC2;PPARGC1A;PFKFB3;...
Fatty acid biosynthesis -1.27 5.59e-1 16/18 (88.89%) ACACA;ACACB;ACSL3;...
Sulfur metabolism -1.30 5.26e-1 9/10 (90%) TST;ETHE1;SQOR;...
Prion disease -1.30 5.21e-1 209/273 (76.56%) ADRM1;CREB1;NDUFB2;...
HIF-1 signaling pathway -1.31 5.26e-1 105/109 (96.33%) INS;PIK3R1;EGLN2;...
Notch signaling pathway -1.32 5.18e-1 49/59 (83.05%) NCOR2;ADAM17;PSEN1;...
MicroRNAs in cancer -1.33 5.01e-1 146/310 (47.1%) MDM2;EZR;PDGFRA;...
Proteoglycans in cancer -1.34 4.84e-1 172/205 (83.9%) FGFR1;MDM2;ERBB4;...
JAK-STAT signaling pathway -1.35 5.02e-1 146/162 (90.12%) PIK3CD;IL10;PDGFB;...
Amoebiasis -1.35 5.32e-1 99/102 (97.06%) CSF2;PRDX1;IL6;...
IL-17 signaling pathway -1.36 5.01e-1 84/94 (89.36%) CCL2;TNFAIP3;CSF2;...
Non-alcoholic fatty liver disease -1.38 4.74e-1 126/155 (81.29%) COX8A;NDUFS2;NR1H3;...
Protein digestion and absorption -1.38 5.00e-1 78/103 (75.73%) COL4A2;COL10A1;CPB2;...
Insulin resistance -1.39 5.14e-1 96/108 (88.89%) RPS6KA1;PPARGC1A;NR1H3;...
PPAR signaling pathway -1.42 4.52e-1 66/74 (89.19%) NR1H3;SLC27A6;FABP3;...
PI3K-Akt signaling pathway -1.49 2.78e-1 317/354 (89.55%) FGF7;RBL2;LAMA3;...
Systemic lupus erythematosus -1.52 2.35e-1 45/135 (33.33%) C1R;C9;CD80;...
Dilated cardiomyopathy -1.53 2.43e-1 86/96 (89.58%) ITGA9;ITGB8;SLC8A2;...
Staphylococcus aureus infection -1.57 1.93e-1 72/95 (75.79%) FPR3;KRT18;KRT13;...
Hypertrophic cardiomyopathy -1.59 2.03e-1 81/90 (90%) ITGA9;ITGB8;SLC8A2;...
Focal adhesion -1.59 2.35e-1 180/201 (89.55%) PIK3R1;EGF;COL6A3;...
Complement and coagulation cascades -1.59 2.74e-1 76/85 (89.41%) PROCR;SERPINB2;SERPINA5;...
Cardiac muscle contraction -1.62 2.79e-1 64/87 (73.56%) COX8A;SLC8A2;MYL3;...
Malaria -1.62 3.52e-1 44/50 (88%) CR1;IL6;THBS3;...
ECM-receptor interaction -1.67 3.94e-1 80/88 (90.91%) SDC1;LAMA3;COL4A5;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.04uM - 3.33uM 24H